cancer showed EN2 auto-antibodies. No significant responses were found in the predisposed group. Anti-EN2 IgG responses were significantly higher in patients with prostate cancer compared to healthy control males and similarly prevalent to anti-NY-ESO-1 responses. Whilst EN2 autoantibodies are not a useful diagnostic or monitoring tool EN2 immunogenicity does provide the rationale to pursue studies using EN2 as an immunotherapeutic target.
are managed by active surveillance). There are currently intense worldwide efforts to establish reliable biomarkers both for the early detection of prostate cancer and also to identify which cancers are likely to progress. We recently reported the diagnostic potential of Engrailed-2 (EN2) protein, a homeodomain-containing transcription factor secreted into the urine of men with prostate cancer [2] . In a follow-up study we further demonstrated that urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer [3] and thus may be useful in deciding which patients to treat and which to monitor closely. Moreover, tissue expression (cytoplasmic, nuclear and membrane) of EN2 was found exclusively in prostate cancer and not normal prostatic epithelium in tissue microarrays and patient specimens. EN2 was expressed equally at all stages of prostate cancer (T stage 1-4)
as well as in metastatic disease (lymph nodes) (Morgan personal communication).
Antibodies fulfil their adaptive immune response commonly to prevent infection.
However, the function of tumour-associated autoantibodies, which bind self-antigens and have escaped self-tolerance, is generally unknown. Autoantibodies can mediate antibody-dependent cell mediated cytotoxicity and complement-dependent cytotoxicity.
They may also enhance antigen cross-presentation and activation of T lymphocytes. It has been shown that IgG responses to tumour-associated proteins exist in cancer patients, making it possible to use human sera to identify immunologically-recognized potential tumour antigens [4] . IgG responses to tissue associated antigens may have diagnostic value, aid in risk stratification in terms of tumour progression or provide a tool for monitoring patients response to treatment. Previous studies have clearly shown 5 a multitude of antibody responses to prostate associated antigens [5] [6] [7] [8] . We proposed that de novo expression of EN2 in prostate cancer could potentially elicit an autoantibody response, and that this could be quantified and potentially used as an adjunct to current diagnostic and monitoring biomarkers.
In this study we assessed the spontaneous antibody response to EN2 in men with prostate cancer, both treatment naive at different stages but also patients who had received optimal treatment. We detected a significantly higher prevalence of IgG responses to EN2 in prostate cancer patients compared to healthy control males, with positive antibody responses being found predominantly in patients with higher volume and more advanced stage prostate cancer.
Materials and Methods

Patient Populations
The study evaluated blood samples from cancer patients, individuals at high risk of developing prostate cancer and healthy volunteer controls. In all cases, written informed consent was obtained and the donation of blood samples for autoantibody evaluation had received approval by the local ethics committee.
Our control groups consisted of men who were unlikely to harbour prostate cancer based on the absence of symptoms, no family history of cancer, a PSA <2 ng/ml (Av age:65; range 40-89). In a similar way, the female controls for the breast and ovarian cancer study were women with no past history of any cancer, no symptoms and no family history of any malignancy. Patients with histological (on routine biopsy) evidence of benign prostatic hypertrophy, prostatic intra-epithelial neoplasia and prostatitis were excluded from the study. These patients have, generally, an abnormal PSA and even with saturation biopsies an underlying malignancy cannot be excluded. In the case of prostatitis the PSA is often markedly raised, and may remain so for 6-9 months.
Despite our large cohorts of patients and controls in the study, the total number of patients with these 3 conditions would have been too small for meaningful statistical comparison.
Blood was taken from prostate cancer patients from the Royal Surrey County Hospital (Guildford, UK). We evaluated four specific cohorts:
(1) Samples from a comprehensive prostate cancer biobank, consisting of the pre- The mean value plus 3 standard deviations calculated from the test results for healthy controls for plasma IgG was used as a cut-off value for evaluation of each assay. This ELISA was standardized using rabbit (EN2, Abcam, UK) and goat Abs (NY-ESO-1, Lifespan BioSciences, Seattle, WA) with specificity for each of the antigens.
Immunoblot Analysis
To confirm ELISA results EN2 detection was performed by running 1g of purified EN2 protein or the control protein DHFR on a NuPAGE gel followed by semi-dry western blotting, blocking using 5% Marvel and chemiluminescent detection. EN2 detection was achieved using 1:1000 dilution HRP-conjugated donkey anti-goat IgG (Jackson ImmunoResearch, UK). To show that plasma or sera antibodies also recognize our recombinant EN2 protein, blots were incubated with patient sera or plasma diluted 1:100 for 24hrs, washed and detected using HRP conjugated goat anti-human IgG (Jackson ImmunoResearch, UK) diluted 1:10,000.
Statistical Analyses
The chi-squared test with a 95% confidence interval was performed using MedCalc to evaluate the statistical significance of differences in the proportion of EN2 or NY-ESO-1 antibody responders between patient cohorts and healthy controls. Differences were considered significant when the probability values obtained from the statistical tests were 0.05 or less.
Results
In order to determine whether circulating EN2-specific antibodies were present in patients and healthy controls, an ELISA was developed using recombinant EN2 protein produced by expression in E.coli. Samples from patients and healthy controls were screened on rEN2 and as a comparison on one of the most immunogenic cancer testis antigens, rNY-ESO-1-coated microplates. In addition samples were also screened against a non-immunogenic murine protein (DHFR) similarly produced in E.coli to eliminate sera/plasma that non-specifically reacted with bacterial contaminants in the 
Patients with prostate cancer demonstrate spontaneous IgG anti-EN2 responses in plasma/serum
(1) We first evaluated IgG anti-EN2 and anti-NY-ESO-1 autoantibody responses in our SUN cohort. These were pre-treatment samples from men with all stages of prostate cancer (Fig 2A) . To be considered positive for an IgG response the cut-off values were calculated as the mean value plus three standard deviations from the data pool of the control sera/plasma samples. We (2) We next evaluated samples from men with a rising PSA level despite optimal hormone treatment, but with no disease radiologically (CRRPSA). We found no significant increase in the proportion of EN2 IgG responders in this group of patients compared to healthy controls. However the proportion of patients within this group responding to NY-ESO-1 was statistically different from healthy controls (p<0.01) (Fig 3A) .
(3) We found that in men with castrate resistant advanced metastatic disease 12/107 patients (11.2%) were confirmed as positive for IgG responses to EN2.
This proportion of EN2 IgG responders was statistically different compared to healthy controls (p<0.001). None of these patients were receiving chemotherapy at the time the blood was drawn (Fig 3B) .
(4) In men at high risk of developing prostate cancer (IMPACT study participants)
no significantly increased IgG responses to EN2 or NY-ESO-1 were detected compared to the age matched healthy control group (Fig 3C) .
Of the patients that demonstrated a positive IgG response to EN2 and/or NYESO-1, from the SUN study cohort only 2 out of the 47 patients showed a response to both antigens, from the CRRPSA cohort none of the Ab positive patients responded to both antigens and from the men with castrate resistant disease with radiological evidence of metastatic disease only 2 out of 19 patients showed a response to both antigens.
Dominant IgG1 and IgG3 response against EN2
21 serum/plasma samples reacting with EN2 were additionally subjected to IgG subclass testing (IgG subclass 1-4). The level of the IgG subclass of the EN2 antibody was determined in each patient using the same ELISA as before but for detection we used subclass-specific secondary antibodies. We predominantly found antibodies from subclass IgG1 and/or IgG3 in all patients. 11/21 patients tested showed both an IgG1
and IgG3 response, 9/21 patients gave only an IgG1 response and one patient showed only an IgG3 response. No significant IgG2 or IgG4 response was observed in any of the patients (Figure 4 ).
EN2 antibody response remains stable in seropositive patients regardless of treatment
From the SUN study cohort sequential follow-up samples were available which allowed us to study the EN2 autoantibody response in a longitudinal manner. From those patients that had demonstrated a positive auto-antibody response to EN2, sequential samples were available from 5 patients under active surveillance, 3 patients who had received radiotherapy and 5 patients who had received a radical prostatectomy. ELISA results on the sequential samples from these patients showed that the antibody response remained stable in all but one of these patients regardless of treatment and over a period of up to 3 years 11 months. In only one of the patients (SUN 147) who had received a radical prostatectomy did the EN2 antibody response fall below the cut-14 off level for positivity following surgery and remained negative for 2 years 10months post-surgery ( Figure 5 ).
No significant detection of anti-EN2 IgG responses in female oncological patients
The assessment of serum/plasma IgG anti-EN2 antibodies in patients with malignancies was extended to female patients with breast or ovarian cancer, cancer types which we have found to have a high prevalence of EN2 expression at the protein level (data not shown). As shown in Figure 6 , autoantibody was rarely detected and was not higher in patients with breast or ovarian cancer compared to female healthy controls. This was in contrast to IgG anti-NY-ESO-1 responses which were clearly found in both female cancer groups at a frequency previously published in the literature [11] . [17] . They found that different antigens were recognized following androgen deprivation compared with vaccine therapies.
In the current study we assessed the levels of auto-antibodies against EN2 in sera from patients with prostate cancer, other cancers and from individuals at high risk groups. This is, to our knowledge, the first assessment of spontaneous immune responses to EN2 in prostate cancer. We have demonstrated a significant increase in anti-EN2 IgG antibodies in patients with prostate cancer as compared to control subjects.
Furthermore the frequency of anti-EN2 IgG responses in our prostate cancer patient cohorts was similar to the number of seropositive patients specific for the highly immunogenic tumour antigen, NY-ESO-1. NY-ESO-1 is a cancer/testis antigen which is expressed in a number of human cancers including prostate cancer [18] . NY-ESO-1 appears to be one of the most immunogenic tumour antigens inducing a humoral immune response and specific CD8 T-cell reactivity in ~50% of patients with advanced NY-ESO-1-expressing tumours [19, 20] . Due to its high immunogenicity and broad expression in a variety of cancers, monitoring of antibody responses to NY-ESO-1 has already been used as a selection criterion for patients enrolling in NY-ESO-1 cancer vaccine trials and as a tool to assess the immunologic and clinical responses of the treatment ( [19, 20, 21] . Notably an elevated EN2 IgG response was not related to an elevated NY-ESO-1 response indicating that a high EN2 response is highly specific
and not related to a general autoimmune phenomenon. The prevalence of humoral immune responses to EN2 within our prostate cancer patient cohorts was similar to what has previously been reported in prostate cancer patients for other prostate cancer associated proteins (11% PSA and 15.5% Her-2/neu) [12] .
We first evaluated pre-treatment sera from men representative of stages 1-4 prostate cancer from a prospective biobank. We found a significant prevalence of IgG responses to EN2 in the cancer patients versus controls and this was comparable to the response frequency to NY-ESO-1 measured in the same samples. [7] .
We then went on to test two groups of patients with castrate resistant disease. Here we found that there were a significantly lower proportion of EN2 IgG responders in those patients with undetectable cancer but a rising PSA (CRRPSA). In contrast the group with metastatic disease displayed EN2 IgG responses comparable to the SUN cohort.
This suggests that detectable disease needs to be present in order for a measurable EN2 IgG response to be present. This is further supported by our finding that there were no significantly elevated anti-EN2 IgG responses or indeed anti-NY-ESO-1 IgG responses in the IMPACT high risk group compared to healthy controls. A number of studies have reported that circulating autoantibodies to tumour associated antigens have been found to be detectable several years before radiographic detection or incidence screening was able to identify the tumours [22] [23] [24] . However, the mechanism underlying their emergence and regulation of their production is not fully understood.
Previous reports have described the detection of specific serum autoantibodies in prediagnostic sera and hence their potential use as a screening tool in asymptomatic high risk populations [22] [23] [24] . Due to the availability of sequential samples from patients within the SUN study cohort we were able to address this by performing a longitudinal assessment of the EN2 autoantibody response in seropositive patients and the effects of different types of treatment on the antibody response. Interestingly in all patients the EN2 autoantibody response persisted over the entire sampling period (up to nearly 4 years in some patients) regardless of the type of treatment received. The only exception was one patient who became EN2 sero-negative following radical prostatectomy. This finding is perhaps not that surprising as it is known that low-level antibodies can persist up to a life-time in an individual following vaccination or infection.
This can be attributed to on-going production from a rapid-turnover of memory B-cell pools [25] or long-lived plasma cells [26] which can be maintained by antigenic stimulation (e.g. persistent antigenic re-exposure) and/or antigen-independent activation mechanisms [27] . One can speculate whether the persistence of the antibody response is due to low levels of residual tumour or simply due to long-lived plasma cells. It is tempting to conclude that the single patient where the antibody response disappeared following surgery was actually cured given the stability of the antibody levels in the majority of patients studied. However, the persistence of the EN2
antibody response in most patients precludes its use as a monitoring tool for response to treatment.
In this study we went on to further characterize the humoral response to EN2 by determining the subclass of antibody induced. It is known that human B cells produce 4 subclasses of IgG (IgG1, IgG2, IgG3, IgG4), with each subclass having different biological functions [28, 29] . The dominant subclasses induced in the antibody response against EN2 were IgG1 and IgG3. Although the clinical significance of the different IgG1 and IgG3 patterns of response observed in our patients cannot be addressed due to the small numbers of patients studied, it is known that the distribution of IgG subclasses within an antibody response is affected by a number of factors including nature of antigen, dose, route of entry and also the host genotype [30] . This was demonstrated in a vaccination study using recombinant CEA where a gradual shift from a predominant IgG1 response at 6 months to an IgG4 response at 15 months was seen [31] . Similar to our findings the humoral response to NY-ESO-1 has also been reported to consist of antibodies of the IgG1 and IgG3 subclass [32] . IgG1 induction results from Th1 type CD4 T-cell activation [33] , whilst immune-complexes consisting of the antigen and IgG1 or IgG3 mainly bind to FcRIIa [34, 35] which is a potent leukocyte activator and stimulates the release of high levels of inflammatory cytokines.
Thus the induction of IgG1 and IgG3 provide favourable conditions for effector T-cell activation in the immune response to EN2. Our group are currently investigating cellular immune responses to EN2.
Interestingly the present work showed that the increased anti-EN2 IgG levels appeared to be more significant in male cancer patients than in female cancer patients. This was in contrast to the auto-antibody response to NY-ESO-1 which was significant in both male and female cancer patients. This gender difference in the humoral immune response has been reported before and further supports the suggestion that sex hormones may significantly affect the humoral immune response to some tumour associated antigens [36, 37] .
In summary, this study has shown that the homeodomain-containing transcription The first two lanes denotes the control experiment using a goat anti-EN2 antibody and donkey anti-goat IgG-HRP secondary antibody to detect the purified recombinant EN2
in lane 1 whereas lane 2 that contained the control protein DHFR remained negative.
Sera from patient 1 and plasma from patients 2 and 3 were EN2 antibody positive in ELISA whereas plasma from patients 4 and 5 were negative in ELISA. antigen was compared between patients and healthy controls using a chi-squared test.
The proportion of patients responding to NY-ESO-1 within the CRRPSA cohort were found to be different from the healthy controls (p<0.01; **) (A). In the castrate resistant disease with radiological evidence of metastatic disease group (B) the proportion of IgG responders to both EN2 and NY-ESO-1 were found to be different from healthy controls (p<0.001; *** and p<0.05;* respectively). No statistical difference in the proportion of IgG responders to either EN2 or NY-ESO-1 were found within individuals at high risk of cancer (IMPACT cohort) compared to healthy controls. Representative results of this longitudinal assessment of the EN2 autoantibody response are shown for patients who were under active surveillance, patients who had received radiotherapy and patients who had undergone radical prostatectomy. All patients studied remained EN2 seropositive (above the cut-off values calculated as the mean value plus three standard deviations from the data pool of the control sera samples, blue line) over the time period studied except patient SUN147 who became sero-negative following radical prostatectomy. 
